ArticleMolecular diversity2026
Discovery of potent biphenyl-macolacin derivatives through a lysine-T/CDHA iterative scanning (LTIS) strategy followed by chemical ligation-based modifications.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The antibiotic biphenyl-macolacin (Bip-macolacin) is a promising drug candidate with good activity against Gram-negative bacteria including several colistin-resistant pathogens, providing a potential structural motif for developing novel antibiotics. Considering the importance of efficient and effective structural optimization in medicinal chemistry studies, we herein report a lysine-T/CDHA iterative scanning (LTIS) strategy to produce Bip-macolacin analogues and identify the modifiable sites, followed by structural derivatization through chemical ligation chemistry. Using this approach, four classes of Bip-macolacin derivatives were prepared conveniently, several of which exhibited antibacterial activities comparable or better than those of Bip-macolacin. The efficacy of representative analogues 5, 18, and 46 was also demonstrated by the resistance development evaluation and hemolysis assay. From this study, a systematic structure-activity relationship of Bip-macolacin was established as a reference for further development of Bip-macolacin-based antibiotics. This novel and powerful strategy also provides more opportunities and valuable options for the structural optimization in future research on peptide therapeutics.
Indexed as
Identifiers
42435191What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.